"Designing Growth Strategies is in our DNA"
The global monoclonal antibody therapy market size was USD 123.03 billion in 2019 and is projected to reach USD 350.10 billion by 2027, exhibiting a CAGR of 14.0% during the forecast period.
In the current scenario, therapeutics monoclonal antibodies are enjoying unprecedented success, revenue growth, accelerated research, and traction owing to their effective clinical outcomes. Monoclonal antibodies such as Remicade, Rituxan, Remicade, Humira, and Herceptin have emerged as blockbuster drugs, which are in turn boosting the market. Apart from this, the market is being flooded by numerous biosilimars owing to less cost, easy approval process and patent expiry. This is also driving the monoclonal antibody therapeutics market. Increasing research funding for the development of novel monoclonal antibodies is expected to favor the market during the forecast period. In December 2019, CARsgen Therapeutics received Investigational New Drug (IND) clearance in China for AB011, a humanized monoclonal antibody for the treatment of gastric and pancreatic adenocarcinoma. This is expected to positively impact this market.
Request a sample to learn more about this report.
Strategic Research Collaborations to Surge the Market
Increased focus of pharmaceutical giants on the development of novel monoclonal antibodies has paved way for major research collaborations which is emerging as a key monoclonal antibody therapy market trends. Owing to the increasing adoption of monoclonal antibody, new manufactures wants to enter the highly competitive market and strategic collaborations can be a useful tool to sustain their position. For example, October 2017, Incyte and MacroGenics, Inc. announced partnership and license agreement for MGA012, an investigational monoclonal antibody of MacroGenics, Inc.
Significant Investment in the Development of Novel Monoclonal Antibody Therapeutics to Boost the Market
monoclonal antibody therapy is a fast emerging as extraordinary tool for the treatment of chronic diseases, especially cancer. Preference towards monoclonal antibody therapy is gradually rising, resulting in blockbuster sales of few products such as Herceptin, Humira and others. This, in turn, has encouraged major pharmaceutical companies for huge research investment in the field of monoclonal antibodies. For example, AstraZeneca, a pharmaceutical giant is conducting phase II clinical trial on Tezepelumab for the treatment of atopic dermatitis. Similar pipeline potential candidates are expected to drive the monoclonal antibody therapy market growth.
Apart from this, green signal form the regulatory authorities for the entry of biosimilars of existing mAb products are further fostering the market value for monoclonal antibody therapy.
Rising Prevalence of Chronic Diseases to Favor the Market
The increasing prevalence of chronic diseases is one of the major factors augmenting this market. Chronic diseases pose a major burden across the globe which is propelling the governments of various countries to put efforts in reducing the cost burden pertaining to their spread. According to the Centers for Disease Control and Prevention, 6 in every 10 adults in the U.S. are suffering from a chronic disease, leading to an annual healthcare cost of US$ 3.5 trillion. Furthermore, unmet patient needs and improving health reimbursement policies for therapeutic monoclonal antibody used for treatment of chronic diseases are projected to fuel the monoclonal antibody therapeutics market growth.
Stringent Regulatory Policies for the Approval Process to Hamper the Market
Despite promising results for monoclonal antibodies in the treatment of various diseases, the long and strict regulations for approval and launch will be a major hindrance on the monoclonal antibodies therapy revenue. Many clinical studies are withdrawn mainly due to failure to meet the stringent regulations and end results framed by the regulatory authorities. In addition to this, monoclonal antibody therapy side effects are other factors restricting the market growth.
To know how our report can help streamline your business, Speak to Analyst
Human Monoclonal Antibody Segment to Dominate the Market Owing to High Humira Sales
On the basis of type, this market can be segmented into human monoclonal antibody, humanized, monoclonal antibody, chimeric monoclonal antibody, and murine monoclonal antibody. The human monoclonal antibody segment accounted for the dominating position. This can be attributed to the higher sales and demand for Humira. Moreover, the entry of Adalimumab biosimilars is expected to augment the segment during 2020-2027. For example, in October 2018, Amgen announced the launch of Amgevita, a biosimilar of adalimumab, in Europe.
The humanized monoclonal antibody segment is poised to surge owing to the increased number of humanized mAb therapies and rising research funding by pharmaceutical companies. Genentech, a company of Roche, is conducting research on Obinutuzumab a humanized anti-CD20 monoclonal antibody for the treatment of end-stage renal disease. This is likely to render remarkable growth to the humanized monoclonal antibody segment. Technological advancement to develop molecular level understanding of diseases, rising ageing population, and expanding applications of monoclonal antibodies are factors contributing to the expansion of the chimeric monoclonal antibody and murine monoclonal antibody segments.
Rising Cancer Cases to Render Dominant Position to the Segment
Based on application, this market is segmented into type cancer, autoimmune diseases, and others. The cancer segment accounted for the maximum portion of the market and is estimated to dominate the market throughout the forecast period. Rising prevalence of cancer, improving health reimbursement policies, and potential pipeline candidates are the major factors attributable for the growth of the segment. According to the WHO, the number of cancer cases in the world is estimated to increase from 18.0 million in 2018 to 24.1 million by 2030. This is expected to augment the cancer segment. The autoimmune disease segment is expected to grow owing to the rising incidences of rheumatoid arthritis, rapid adoption of biological therapies, and new product lunches. The other segment is projected to expand during the forecast period owing to the emerging use of monoclonal antibody therapy for migranes, eczema, respiratory diseases, and others.
Hospital Pharmacy to Account for Major Portion of the Market
In terms of distribution channel, this market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment generated the maximum revenue in 2019 owing to the improving guidelines, favoring health reimbursement policies, and active government interventions for chronic diseases. The retail pharmacy segment for monoclonal antibody therapy is anticipated to grow during the forecast period mainly due to the increasing focus by manufacturers to expand distribution network, significant increase in number of cancer cases, and improving health infrastructure. Growth of the online stores segment is likely to propel owing to the improving patient convenience, rising adoption of online channels, and attractive discounts and coupons on online sales.
North America Monoclonal Antibody Therapy Market Size, 2019 (USD Billion)
To get more information on the regional analysis of this market, Request a sample
The monoclonal antibody therapy market size in North America stood at USD 58.8 billion in 2019. Factors attributed for the dominant share of North America are new product launches, increasing research funding and collaborations, and increasing prevalence of chronic diseases. According to the National Cancer Institute, in 2020 there will be 1.8 million new cancer cases in the U.S. This is estimated to increase the demand for monoclonal antibody therapeutics in North America. In Europe, the market is poised to surge owing to favorable health reimbursement and easy approval and launch of biosimilars. In October 2018, Biogen announced the launch of Imraldi, an adalimumab biosimilar, which will help the market to flourish in Europe. Rising incidences of arthritis and inflammatory diseases, increasing geriatric population, and growing preference for biosimilars are primary reasons for the expansion of the market in Asia Pacific. The market in the Middle East & Africa and Latin America is expected to gain significant momentum owing to increased focus of manufacturers towards emerging countries, unmet patient needs, and improving health spending.
AbbVie and F. Hoffmann-La Roche Ltd. to Hold the Leading Position
In terms of this market revenue, F. Hoffmann-La Roche Ltd. accounted for the maximum portion of the market which can be attributed to the increasing sale of Herceptin. AbbVie, on the other hand is ranked second in the market owing to the increased sales of Humira. In 2018, the company generated a sale of US$ 19.0 billion in 2019. Tough Humria still has exclusivity in the U.S., launch of adalimumab biosimilars in Europe is expected to effect the position of AbbVie.
The monoclonal antibody therapy market report offers a detailed analysis of numerous factors affecting the market. These include opportunities, growth drivers, threats, key developments, and restraints. In addition to this, the report further helps in analyzing, segmenting, and defining the market based on different segments such as type, application, and distribution channel. It strategically analyzes several strategies and provides various key insights such as prevalence of major diseases for key countries, patent snapshot, pipeline analysis, new product launches, key mergers & acquisition, joint ventures, and others.
To gain extensive insights into the market, Request for Customization
Value (USD billion)
By Distribution Channel
The value of the global market was USD 123.03 billion in 2019.
Fortune Business Insights says that the market is projected to reach USD 350.10 billion by 2027.
The value of the market in North America was USD 58.8 billion in 2019.
The market is projected to rise at a CAGR of 14.0% during the forecast period (2020-2027).
Human monoclonal antibody segmentis the leading segment in this market during the forecast period.
Significant investment for the development of novel monoclonal antibody therapeutics and rising prevalence of chronic diseases are the key factors driving the market.
AbbVie Inc. and F.Hoffmann-La Roche Ltd. are the top players in the market.
North America is expected to hold the highest market share.
Strategic research collaborations is the key trends of the market.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry